riva-sildenafil tablet
laboratoire riva inc. - sildenafil (sildenafil citrate) - tablet - 100mg - sildenafil (sildenafil citrate) 100mg - phosphodiesterase type 5 inhibitors
accel-sildenafil tablet
accel pharma inc - sildenafil (sildenafil citrate) - tablet - 25mg - sildenafil (sildenafil citrate) 25mg - phosphodiesterase type 5 inhibitors
accel-sildenafil tablet
accel pharma inc - sildenafil (sildenafil citrate) - tablet - 50mg - sildenafil (sildenafil citrate) 50mg - phosphodiesterase type 5 inhibitors
accel-sildenafil tablet
accel pharma inc - sildenafil (sildenafil citrate) - tablet - 100mg - sildenafil (sildenafil citrate) 100mg - phosphodiesterase type 5 inhibitors
apo-sildenafil 50mg tablets
apotex inc. - sildenafil (sildenafil citrate) - tablets - 50mg
apo-sildenafil 25mg tablets
apotex inc. - sildenafil (sildenafil citrate) - tablets - 25mg
sildenafil- sildenafil tablet, film coated
lake erie medical dba quality c - sildenafil citrate (unii: bw9b0ze037) (sildenafil - unii:3m7ob98y7h) - sildenafil 20 mg - sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (who group i) in adults to improve exercise ability and delay clinical worsening. the delay in clinical worsening was demonstrated when sildenafil tablets were added to background epoprostenol therapy [see clinical studies (14)] . studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with new york heart association (nyha) functional class ii to iii symptoms and idiopathic etiology (71%) or associated with connective tissue disease (ctd) (25%). sildenafil tablets are contraindicated in patients with: - concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see warnings and precautions (5.2)] . - concomitant use of riociguat, a guanylate cyclase stimulator. pde5 inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat. - known hypersensitivity to sildenafil or any component
sildenafil- sildenafil tablet
nucare pharmaceuticals, inc. - sildenafil citrate (unii: bw9b0ze037) (sildenafil - unii:3m7ob98y7h) - sildenafil 20 mg - sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (who group i) in adults to improve exercise ability and delay clinical worsening. the delay in clinical worsening was demonstrated when sildenafil tablets were added to background epoprostenol therapy [see clinical studies (14) ]. studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with new york heart association (nyha) functional class ii-iii symptoms and idiopathic etiology (71%) or associated with connective tissue disease (ctd) (25%). sildenafil tablets are contraindicated in patients with: - concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see warnings and precautions (5.2)] . - known hypersensitivity to sildenafil or any component of the tablet. hypersensitivity, including anaphylactic reaction, anaphylactic shock and anaphylactoid reaction, has been reported in association with the use
sildenafil- sildenafil tablet
american health packaging - sildenafil citrate (unii: bw9b0ze037) (sildenafil - unii:3m7ob98y7h) - sildenafil 20 mg - sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (who group i) in adults to improve exercise ability and delay clinical worsening. the delay in clinical worsening was demonstrated when sildenafil tablets were added to background epoprostenol therapy [see clinical studies (14)]. studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with new york heart association (nyha) functional class ii-iii symptoms and idiopathic etiology (71%) or associated with connective tissue disease (ctd) (25%). sildenafil tablets are contraindicated in patients with: - concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see warnings and precautions (5.2)] . - concomitant use of riociguat, a guanylate cyclase stimulator. pde-5 inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat. - known hypersensitivity to sildenafil or any component of
sildenafil tablet
methapharm inc - sildenafil (sildenafil citrate) - tablet - 25mg - sildenafil (sildenafil citrate) 25mg - phosphodiesterase type 5 inhibitors